CLDN11: Claudin 11 - A Key Tight Junction Protein in Myelination and CNS Function

Comprehensive genomic, transcriptomic, and proteomic analysis of CLDN11, a critical component of central nervous system myelin and blood-brain barrier integrity.

Gene Information Card

Symbol CLDN11
Full Name Claudin 11
Gene Type Protein coding
Chromosomal Location 3q26.2
NCBI Gene ID 5010 ncbi.nlm.nih.gov/gene/5010
Ensembl ID ENSG00000132965
UniProt ID O75508
OMIM ID 601326
HGNC ID 2037
Aliases OSP, OTM

Description

CLDN11 (Claudin 11) encodes a member of the claudin family of tight junction proteins. This protein is a major component of central nervous system myelin, specifically localized to the tight junctions of oligodendrocytes and Schwann cells. It plays a crucial role in the formation and maintenance of the blood-brain barrier and in the electrical insulation of axons. Mutations in CLDN11 are associated with hypomyelinating leukodystrophy and have been implicated in multiple sclerosis and certain cancers.

Disease Associations

Disease category Pathophysiological mechanism Genomic evidence
Hypomyelinating leukodystrophy 22 (HLD22) Loss-of-function mutations in CLDN11 disrupt tight junction formation in oligodendrocytes, leading to impaired myelination and neurological deficits. ClinVar, OMIM
Multiple sclerosis Reduced CLDN11 expression in CNS lesions correlates with blood-brain barrier breakdown and demyelination. NCBI Gene, PubMed
Schizophrenia Altered CLDN11 expression in prefrontal cortex has been observed in postmortem studies, suggesting a role in synaptic and myelin integrity. NCBI Gene, PubMed
Glioblastoma CLDN11 is frequently downregulated in glioblastoma, contributing to increased tumor cell invasion and blood-brain barrier disruption. COSMIC, PubMed

Expression Profile

Tissue Expression
Tissue nTPM level
Brain 28.5 High
Testis 12.3 Medium
Spinal cord 25.1 High
Lung 1.2 Low
Liver 0.5 Not detected
Cell Line Expression
Cell Line nTPM Notes
Oligodendrocytes 35.0 Primary CNS myelin-forming cells
Schwann cells 22.4 Peripheral nervous system
U-87 MG (glioblastoma) 0.8 Low expression; loss correlates with invasion
SH-SY5Y (neuroblastoma) 5.2 Moderate expression
Data source:Human Protein Atlas(proteinatlas.org)

Mutations & Variants

Hotspot Mutations
Variant Type Frequency Functional Description
c.200C>T (p.Pro67Leu) Missense Rare Loss of tight junction function; associated with HLD22
c.1A>G (p.Met1Val) Start loss Rare Complete loss of protein; severe hypomyelination
c.448G>A (p.Gly150Arg) Missense Rare Impaired protein trafficking; reduced barrier function
Mutation functional classification

Loss of Function (LOF)

Missense and start-loss mutations that disrupt protein folding, trafficking, or tight junction assembly, leading to hypomyelination and leukodystrophy.

Gain of Function (GOF)

Not reported for CLDN11.

Dominant Negative (DN)

Not reported for CLDN11.

Gene Ontology (GO)

• Tight junction • Cell-cell junction
• Myelin sheath • Blood-brain barrier
• Protein homooligomerization • Calcium-independent cell-cell adhesion

Pathways

• Tight junction (KEGG hsa04530)
• Cell adhesion molecules (CAMs) (KEGG hsa04514)
• Myelination (Reactome R-HSA-9616222)

Protein Summary

Claudin 11 is a 23.5 kDa transmembrane protein with four transmembrane domains, two extracellular loops, and intracellular N- and C-termini. It forms tight junction strands through homophilic and heterophilic interactions with other claudins. In the CNS, it is essential for the radial component of myelin in oligodendrocytes, contributing to the high-resistance barrier that enables saltatory conduction. The protein is also expressed in testis Sertoli cells, where it contributes to the blood-testis barrier.

Related Products

Product name Cat.No. Species Gene ID
CLDN11 Knockout HEK293 Cell Line EDJ-KQ50497 Human 5010 Details Get a Quote
CLDN11 Knockout HeLa Cell Line EDJ-KQ54062 Human 5010 Details Get a Quote
CLDN11 Knockout A-549 Cell Line EDJ-KQ62550 Human 5010 Details Get a Quote
CLDN11 Knockout HCT 116 Cell Line EDJ-KQ71022 Human 5010 Details Get a Quote
Contact Us
*
*
*
How did you hear about us: